CN113101375A - Chitosan grafted salicylic acid microcapsule and preparation method thereof - Google Patents

Chitosan grafted salicylic acid microcapsule and preparation method thereof Download PDF

Info

Publication number
CN113101375A
CN113101375A CN202110498044.1A CN202110498044A CN113101375A CN 113101375 A CN113101375 A CN 113101375A CN 202110498044 A CN202110498044 A CN 202110498044A CN 113101375 A CN113101375 A CN 113101375A
Authority
CN
China
Prior art keywords
salicylic acid
chitosan
solution
stirring
emulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110498044.1A
Other languages
Chinese (zh)
Inventor
徐春涛
李正伦
黄颖俊
练金银
莫楚贤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huizhou Lyuya Biomaterial Co ltd
Original Assignee
Huizhou Lyuya Biomaterial Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huizhou Lyuya Biomaterial Co ltd filed Critical Huizhou Lyuya Biomaterial Co ltd
Priority to CN202110498044.1A priority Critical patent/CN113101375A/en
Publication of CN113101375A publication Critical patent/CN113101375A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/736—Chitin; Chitosan; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/54—Polymers characterized by specific structures/properties
    • A61K2800/544—Dendrimers, Hyperbranched polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/60—Particulates further characterized by their structure or composition
    • A61K2800/61—Surface treated
    • A61K2800/62—Coated
    • A61K2800/624—Coated by macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a chitosan grafted salicylic acid microcapsule and a preparation method thereof. Salicylic acid is used as a core material, chitosan is used for grafting the salicylic acid through weak bond combination, a special compound emulsifier is screened, noble metal is used as a catalyst, stable charged liquid drops prepared by the core material are used as a template, the salicylic acid emulsion and the chitosan are catalyzed by the noble metal catalyst to carry out graft polymerization reaction, and nano charged particles are formed; on the basis, salicylic acid particles are reinforced by adopting wall materials with opposite charges, and finally, a curing agent calcium chloride is adopted for encapsulation to form stable nanoparticles. The chitosan grafted salicylic acid microcapsule reduces the irritation of salicylic acid, increases the solubility and has wide application prospect in the fields of daily chemicals and medicines.

Description

Chitosan grafted salicylic acid microcapsule and preparation method thereof
Technical Field
The invention relates to the technical field of cosmetics and medicines, in particular to a salicylic acid grafting technology.
Background
Salicylic Acid (SA) is a simple phenolic compound, and is widely used in the fields of medicines due to its various pharmacological activities such as sterilization, antisepsis, anti-inflammation, anti-rheumatism, etc. Salicylic acid is also one of common functional components of cosmetics, and has the effects of whitening skin, removing acnes and the like when being used on the skin. Salicylic acid is a fat-soluble compound, and its use is limited due to its strong irritation to the skin. The research adopts layer-by-layer self-assembly to prepare nano-encapsulated salicylic acid, aims to improve the water solubility of the salicylic acid, improve the controlled slow release performance of the salicylic acid, reduce the irritation and is applied to related industries such as cosmetics and the like.
In 1763, Edmund Stone et al, UK, first discovered that willow bark has a strong astringent effect on skin and can treat malaria and fever, and later discovered that it is the effect of salicylic acid glycosides contained in willow bark. The salicylic acid anti-inflammatory drug is the earliest and most widely applied class of non-steroidal anti-inflammatory drugs and mainly comprises salicylic acid, sodium salicylate, aspirin and the like, wherein the pH value of a saturated aqueous solution of the salicylic acid is 2.4, the salicylic acid has a corrosion effect and is only used for external application, and the salicylic acid mainly takes metabolites of the salicylic acid drugs to play an anti-inflammatory effect in a human body. The result of pharmacokinetic research on aspirin and salicylic acid by Zhang Qingjun and the like shows that aspirin is metabolized into salicylic acid after acting in a human body, the salicylic acid can play an anti-inflammatory role at an inflammation part, and although the action principles of the salicylic acid and the aspirin are different, the anti-inflammatory roles of the salicylic acid and the aspirin are equivalent. Lucky et al consider topical salicylic acid as a worldwide recognized safe acne-removing ingredient. Bashir et al believe that the mechanism of action of salicylic acid is that salicylic acid can dissolve the substance forming the structure between corneocytes under the condition of not affecting the active epidermal structure, so that the cuticle is exfoliated to generate desquamation, the excessively thick cuticle is removed, and the skin metabolism is promoted. In addition, salicylic acid has certain anti-aging effect and has no genetic toxicity and phototoxicity. Compared with fruit acid, salicylic acid has the advantage of no photosensitivity, and the glycolic acid and the salicylic acid are respectively and locally applied to human skin by Kornhauser and the like for a short time, are irradiated by simulated sunlight every monday to friday for 3.5 weeks, and the glycolic acid is found to increase the sensitivity of the human skin to the sunlight, but the salicylic acid does not have the phenomenon.
Figure BDA0003055243160000021
Schematic diagram of intermolecular hydrogen bonds of chitosan oligosaccharide molecular chain
Chitosan (chitosan), the only basic aminopolysaccharide present in large quantities in nature. Rouget first discovered by treating chitin with concentrated KOH, which is a biopolymer obtained from chitin (chitin) by deacetylation. Chitin is widely present in cell walls of crustaceans such as shrimp, crab, insect, etc., and algae and fungi, and is abundant, and the yield per year in nature is 1010-1011Ton, the second largest polysaccharide to cellulose only. The chemical name of the chitosan is beta- (1,4) -2-amino-2-deoxy-D-glucan, the molecular chain of the chitosan usually contains two structural units of N-aminoglucan and N-acetamido glucan, and the proportion of the two structural units is different along with different deacetylation degrees, so that the percentage of the aminoglucan unit in the total structural units is represented by the deacetylation degree. The degree of deacetylation determines the amino (NH) groups on the macromolecular chain2) The content of (a). As the deacetylation degree is increased, the charged groups of chitosan in a dilute acid solution are increased due to protonation of amino groups, the charge density of polyelectrolyte is increased, and the properties, the structure and the performance of the chitosan are obviously changed.
In recent years, chitosan is widely applied to the preparation of nano-capsule wall materials in the fields of food, medicine, cosmetics, textile perfuming and the like, and the reasons are summarized as the following: the chitosan has a good function of controlling the release of active substances; the chitosan is easy to dissolve in 1-3% acetic acid water solution, so that toxic organic solvent is avoided being used when the nano particles are prepared; chitosan is a linear polyamine molecule, contains a large amount of free amino groups, and is easy to generate a crosslinking reaction; the chitosan is expressed as cationic electrolyte in an acidic environment and can perform electrostatic interaction with multivalent anionic electrolyte to form a firm wall material; the good film forming property of the chitosan increases the retention time of the chitosan on a carrier; the chitosan has no toxicity, bacteriostasis and sterilization and has extremely high biocompatibility.
Sodium Alginate (Al) with molecular formula of C6H7O6Na)nThe glue is extracted from brown seaweed such as kelp, and is white or yellowish powder, odorless, tasteless, and hygroscopic. It is a mixture of polyuronic acids, mainlyUnbranched, higher charge density linear block copolymers consisting of α -L-mannuronic acid (M units) and β -D-guluronic acid (G units) linked by α -1, 4-glycosidic linkages and consisting of different ratios of GM, MM and GG segments. It is easy to dissolve in water, insoluble in organic solvent, and possesses the excellent characteristics of thickening, suspending, emulsifying, stabilizing, forming gel and film, so that it can be extensively used in the fields of food, printing and dyeing, medicine, cosmetics and other chemical industries.
Figure BDA0003055243160000031
Chemical structural formula of sodium alginate
Disclosure of Invention
The invention aims to solve the problems that salicylic acid is difficult to dissolve in water and has excessive skin irritation in the market at present, and provides a method for grafting salicylic acid and preparing a microcapsule by combining chitosan through a weak bond so as to solve the problems that salicylic acid is skin irritation and difficult to dissolve in water.
In order to achieve the purpose, the invention adopts the following technical scheme:
a preparation method of chitosan grafted salicylic acid microcapsules comprises the following steps:
(1) putting core material salicylic acid and a compound emulsifier into a beaker, adding deionized water, and carrying out water bath reaction at 10-100 ℃ to obtain a stable negative-charged liquid drop primary emulsion polymer (NEI);
(2) preparing a chitosan solution, adding an acetic acid/sodium acetate buffer solution for dissolving, and controlling the pH value of the solution to be 3-4.5;
(3) adding the solution obtained in the step (1) into the solution obtained in the step (2), adding a noble metal catalyst, and carrying out catalytic grafting reaction in a water bath at the temperature of 10-100 ℃ to obtain a second-level emulsion (NEII) with positively charged droplets;
(4) preparing sodium alginate aqueous solution, and controlling the pH value to be 6-8;
(5) adding the secondary emulsion obtained in the step (3) into the solution obtained in the step (4), and uniformly stirring; carrying out water bath reaction at 10-100 ℃ to obtain the negative charged droplet tertiary emulsion (NEIII).
(6) Adding the calcium chloride solution into the tertiary emulsion obtained in the step (5), and uniformly stirring; reacting in water bath at 10-100 ℃ to obtain the chitosan grafted salicylic acid microcapsule.
Preferably, in the preparation method, the mass ratio of the core material salicylic acid and the compound emulsifier in the step (1) is 1:0.1-1: 10.
Preferably, in the preparation method, the compound emulsifier in the step (1) is tween-80 and sodium lauryl amphoacetate, and the weight ratio of the tween-80 to the sodium lauryl amphoacetate is 1: 10-20: 1.
Preferably, in the above preparation method, the noble metal in step (3) is gold, palladium, molybdenum or copper.
Compared with the prior art, the invention has the following beneficial effects: salicylic acid is used as a core material, chitosan is used for grafting the salicylic acid through weak bond combination, a special compound emulsifier is screened, noble metal is used as a catalyst, stable charged liquid drops prepared by the core material are used as a template, the salicylic acid emulsion and the chitosan are catalyzed by the noble metal catalyst to carry out graft polymerization reaction, and nano charged particles are formed; on the basis, salicylic acid particles are reinforced by adopting wall materials with opposite charges, and finally, a curing agent calcium chloride is adopted for encapsulation to form stable nanoparticles. The chitosan grafted salicylic acid microcapsule reduces the irritation of salicylic acid, increases the solubility and has wide application prospect in the fields of daily chemicals and medicines.
Drawings
FIG. 1 is a thermogravimetric analysis of chitosan salicylate graft copolymer;
FIG. 2 is an infrared spectrum of chitosan (a), chitosan/salicylic acid nanocapsules (b) and salicylic acid (c);
FIG. 3 is a TEM image of a graft copolymer of salicylic acid: a is a chitosan grafting picture, and B is a picture after layer-by-layer assembly and packaging, and the particles shown as B are slightly larger than the particles A after packaging;
FIG. 4 is a slow release diagram of a chitosan salicylic acid graft copolymer.
Detailed Description
Example 1
Weighing 1.0g of Tween-80 (Tween-80) and sodium lauryl amphoteric acetate (LAD-30) and placing the weighed substances in a beaker, wherein the LAD-30 accounts for 10% of the total mass of the emulsifier, adding 2.0g of 50% salicylic acid ethanol solution, uniformly stirring, placing in a water bath at 30 ℃, adjusting the stirring speed to 750rpm, rapidly adding 50mL of deionized water, and stirring for 15min to obtain milky primary emulsion (NEI). Slowly dripping NEI into chitosan solution with the same volume, adding noble metal catalyst, catalyzing graft reaction for 5h at the reaction temperature of 50 ℃, and stirring and assembling to obtain secondary emulsion (NEII). Weighing 0.3g of sodium alginate in a beaker, adding 100mL of deionized water, stirring for dissolving, preparing a sodium alginate solution with the concentration of 3.00mg/mL, taking 100mL of NEII, controlling the stirring speed to be 750rpm, slowly adding the NEII into the sodium alginate solution, and stirring for 15min at room temperature to obtain a tertiary emulsion (NEIII). Preparing 10.0mg/mL calcium chloride solution, taking 200mL NEIII, controlling the stirring speed to be 750rpm, slowly adding into the calcium chloride solution, and stirring at room temperature for 15min to obtain the salicylic acid nano-capsule. Standing for 12h, and freeze-drying to obtain salicylic acid solid nano-capsule particles.
Example 2
Weighing 1.0g of Tween-80 (Tween-80) and sodium lauryl amphoteric acetate (LAD-30) and placing the weighed substances in a beaker, wherein the LAD-30 accounts for 20% of the total mass of the emulsifier, adding 3.0g of 50% salicylic acid ethanol solution, uniformly stirring, placing in a water bath at 30 ℃, adjusting the stirring speed to 750rpm, rapidly adding 50mL of deionized water, and stirring for 15min to obtain milky primary emulsion (NEI). Slowly dripping NEI into chitosan solution with the same volume, adding noble metal catalyst, catalyzing graft reaction for 4h at the reaction temperature of 50 ℃, and stirring and assembling to obtain secondary emulsion (NEII). Weighing 0.3g of sodium alginate in a beaker, adding 100mL of deionized water, stirring for dissolving, preparing a sodium alginate solution with the concentration of 3.00mg/mL, taking 100mL of NEII, controlling the stirring speed to be 750rpm, slowly adding the NEII into the sodium alginate solution, and stirring for 15min at room temperature to obtain a tertiary emulsion (NEIII). Preparing 10.0mg/mL calcium chloride solution, taking 200mL NEIII, controlling the stirring speed to be 750rpm, slowly adding into the calcium chloride solution, and stirring at room temperature for 15min to obtain the salicylic acid nano-capsule. Standing for 12h, and freeze-drying to obtain salicylic acid solid nano-capsule particles.
Example 3
Weighing 1.0g of Tween-80 (Tween-80) and sodium lauryl amphoteric acetate (LAD-30) and placing the weighed substances in a beaker, wherein the LAD-30 accounts for 30% of the total mass of the emulsifier, adding 2.0g of 50% salicylic acid ethanol solution, uniformly stirring, placing in a water bath at 30 ℃, adjusting the stirring speed to 750rpm, rapidly adding 50mL of deionized water, and stirring for 15min to obtain milky primary emulsion (NEI). Slowly dripping NEI into chitosan solution with the same volume, adding noble metal catalyst, catalyzing graft reaction for 4h at the reaction temperature of 60 ℃, and stirring and assembling to obtain secondary emulsion (NEII). Weighing 0.3g of sodium alginate in a beaker, adding 100mL of deionized water, stirring for dissolving, preparing a sodium alginate solution with the concentration of 3.00mg/mL, taking 100mL of NEII, controlling the stirring speed to be 750rpm, slowly adding the NEII into the sodium alginate solution, and stirring for 15min at room temperature to obtain a tertiary emulsion (NEIII). Preparing 10.0mg/mL calcium chloride solution, taking 200mL NEIII, controlling the stirring speed to be 750rpm, slowly adding into the calcium chloride solution, and stirring at room temperature for 15min to obtain the salicylic acid nano-capsule. Standing for 12h, and freeze-drying to obtain salicylic acid solid nano-capsule particles.
Example 4
Weighing 1.0g of Tween-80 (Tween-80) and sodium lauryl amphoteric acetate (LAD-30) and placing the weighed substances in a beaker, wherein the LAD-30 accounts for 50% of the total mass of the emulsifier, adding 2.0g of 50% salicylic acid ethanol solution, uniformly stirring, placing in a water bath at 30 ℃, adjusting the stirring speed to 750rpm, rapidly adding 50mL of deionized water, and stirring for 15min to obtain milky primary emulsion (NEI). Slowly dripping NEI into chitosan solution with the same volume, adding noble metal catalyst, catalyzing graft reaction for 6h at the reaction temperature of 60 ℃, and stirring and assembling to obtain secondary emulsion (NEII). Weighing 0.3g of sodium alginate in a beaker, adding 100mL of deionized water, stirring for dissolving, preparing a sodium alginate solution with the concentration of 2.00mg/mL, taking 150mL of NEII, controlling the stirring speed to be 750rpm, slowly adding the NEII into the sodium alginate solution, and stirring for 15min at room temperature to obtain a tertiary emulsion (NEIII). Preparing 20.0mg/mL calcium chloride solution, taking 100mL NEIII, controlling the stirring speed to be 750rpm, slowly adding into the calcium chloride solution, and stirring at room temperature for 15min to obtain the salicylic acid nano-capsule. Standing for 12h, and freeze-drying to obtain salicylic acid solid nano-capsule particles.
Example 5
Weighing 1.0g of Tween-80 (Tween-80) and sodium lauryl amphoteric acetate (LAD-30) and placing the weighed substances in a beaker, wherein the LAD-30 accounts for 60% of the total mass of the emulsifier, adding 3.0g of 50% salicylic acid ethanol solution, uniformly stirring, placing in a water bath at 30 ℃, adjusting the stirring speed to 750rpm, rapidly adding 50mL of deionized water, and stirring for 15min to obtain milky primary emulsion (NEI). Slowly dripping NEI into chitosan solution with the same volume, adding noble metal catalyst, catalyzing graft reaction for 6h at the reaction temperature of 70 ℃, and stirring and assembling to obtain secondary emulsion (NEII). Weighing 0.3g of sodium alginate in a beaker, adding 100mL of deionized water, stirring for dissolving, preparing a sodium alginate solution with the concentration of 4.00mg/mL, taking 100mL of NEII, controlling the stirring speed to be 750rpm, slowly adding the NEII into the sodium alginate solution, and stirring for 15min at room temperature to obtain a tertiary emulsion (NEIII). Preparing 30.0mg/mL calcium chloride solution, taking 200mL NEIII, controlling the stirring speed to be 750rpm, slowly adding into the calcium chloride solution, and stirring at room temperature for 15min to obtain the salicylic acid nano-capsule. Standing for 12h, and freeze-drying to obtain salicylic acid solid nano-capsule particles.
Example 6
Weighing 1.0g of Tween-80 (Tween-80) and sodium lauryl amphoteric acetate (LAD-30) and placing the weighed substances in a beaker, wherein the LAD-30 accounts for 70% of the total mass of the emulsifier, adding 2.0g of 50% salicylic acid ethanol solution, uniformly stirring, placing in a water bath at 30 ℃, adjusting the stirring speed to 750rpm, rapidly adding 50mL of deionized water, and stirring for 15min to obtain milky primary emulsion (NEI). Slowly dripping NEI into chitosan solution with the same volume, adding noble metal catalyst, catalyzing graft reaction for 7h at the reaction temperature of 40 ℃, and stirring and assembling to obtain secondary emulsion (NEII). Weighing 0.5g of sodium alginate in a beaker, adding 100mL of deionized water, stirring for dissolving, preparing a sodium alginate solution with the concentration of 2.00mg/mL, taking 100mL of NEII, controlling the stirring speed to be 750rpm, slowly adding the NEII into the sodium alginate solution, and stirring for 15min at room temperature to obtain a tertiary emulsion (NEIII). Preparing 30.0mg/mL calcium chloride solution, taking 100mL NEIII, controlling the stirring speed to be 750rpm, slowly adding into the calcium chloride solution, and stirring at room temperature for 15min to obtain the salicylic acid nano-capsule. Standing for 12h, and freeze-drying to obtain salicylic acid solid nano-capsule particles.
Example 7
Weighing 1.0g of Tween-80 (Tween-80) and sodium lauryl amphoteric acetate (LAD-30) and placing the weighed substances in a beaker, wherein the LAD-30 accounts for 80% of the total mass of the emulsifier, adding 5.0g of 50% salicylic acid ethanol solution, uniformly stirring, placing in a water bath at 30 ℃, adjusting the stirring speed to 750rpm, rapidly adding 50mL of deionized water, and stirring for 15min to obtain milky primary emulsion (NEI). Slowly dripping NEI into chitosan solution with the same volume, adding noble metal catalyst, catalyzing grafting reaction for 9h at the reaction temperature of 40 ℃, and stirring and assembling to obtain secondary emulsion (NEII). Weighing 0.3g of sodium alginate in a beaker, adding 100mL of deionized water, stirring for dissolving, preparing a sodium alginate solution with the concentration of 5.00mg/mL, taking 100mL of NEII, controlling the stirring speed to be 750rpm, slowly adding the NEII into the sodium alginate solution, and stirring for 15min at room temperature to obtain a tertiary emulsion (NEIII). Preparing 40.0mg/mL calcium chloride solution, taking 100mL NEIII, controlling the stirring speed to be 750rpm, slowly adding into the calcium chloride solution, and stirring at room temperature for 15min to obtain the salicylic acid nano-capsule. Standing for 12h, and freeze-drying to obtain salicylic acid solid nano-capsule particles.
Example 8 test experiment
The results of the tests performed on the salicylic acid graft nanocapsules obtained in example 1 are shown in tables 1 to 5 and FIGS. 1 to 4, and the results are described below with reference to FIGS. 1 to 4 and tables 1 to 5: table 1 illustrates that the salicylic acid graft nanocapsules have excellent radical scavenging ability; table 2 shows that the salicylic acid graft nanocapsules have good bacteriostatic effects on three acne pathogens; tables 3 and 4 illustrate that the minimum inhibitory concentration of the salicylic acid graft nanocapsule on three acne bacteria is consistent with that of salicylic acid and is not weakened due to grafting; table 5 shows that chitosan-grafted salicylic acid has good solubility in water. FIGS. 1 and 2 show the thermogravimetric and infrared spectra of salicylic acid graft copolymer, respectively, showing that salicylic acid is successfully grafted with chitosan; FIG. 1 is a thermogravimetric analysis of chitosan salicylate graft copolymer. (Shell)The oligosaccharide shows two weight loss stages at 50-100 ℃ and 257 ℃, which are respectively corresponding to the dehydration and thermal cracking of the chitosan oligosaccharide; the melting point of the salicylic acid is 159 ℃, and the vaporization decomposition peak is 231 ℃; the melting point of the physical mixture of the chitosan oligosaccharide and the salicylic acid is 159 ℃, the vaporization temperature is 219 ℃, and the degradation temperature is 257 ℃, which indicates that the chitosan oligosaccharide and the salicylic acid do not react, the chitosan oligosaccharide/salicylic acid microcapsule starts to melt and decompose at 231 ℃, the weight loss temperature is obviously lagged behind that of the pure component and the mixture, and the salicylic acid and the chitosan oligosaccharide form a graft and then the decomposition of the salicylic acid is hindered in the heating process, so that the thermal stability of the salicylic acid is improved). FIG. 2 is an infrared spectrum of the chitosan salicylic acid graft copolymer. (salicylic acid. sigma.)C＝OPeak (1658 cm)-1) Weakened and shifted to 1674cm after encapsulation-1And 1209cm-1The in-plane bending vibration of-OH of aromatic acid at b is weakened, and the characteristic peaks indicate that the chitosan oligosaccharide and salicylic acid have interaction; 3236cm in salicylic acid-1To form a peak of-OH in a hydrogen bond association state, this peak was masked in the microcapsule, demonstrating that salicylic acid was embedded by chitosan oligosaccharide). FIG. 3 is a TEM image of a graft copolymer of salicylic acid, from which it is confirmed that the salicylic acid graft is encapsulated and nano-sized, and it is shown that the size of the particles can be controlled; panel A is a chitosan grafted picture and panel B is a layer-by-layer assembled encapsulated picture showing that the particles of B are slightly larger than the particles of A after encapsulation. FIG. 4 demonstrates that salicylic acid grafts have good sustained release properties. From fig. 4, it can be seen that the chitosan salicylic acid copolymer has a significant slow release effect, and after 3 hours of release, the untreated salicylic acid is released by 70%, while the graft is released by only 50%, and the chitosan salicylic acid copolymer has a significant slow release effect.
TABLE 1 antioxidant Activity of salicylic acid and salicylic acid grafted nanocapsules
Figure BDA0003055243160000081
TABLE 2 results of zone of inhibition of 3 acne pathogens by salicylic acid, salicylic acid grafted nanocapsules and chitosan oligosaccharide
Figure BDA0003055243160000082
Figure BDA0003055243160000091
Note: "-" indicates insensitivity, the diameter of the zone of inhibition < 7 mm; the + represents sensitivity, and the diameter of a bacteriostatic circle is 7-10 mm; the "+ +" indicates sensitivity, and the diameter of the inhibition zone is 10-15 mm. a. b and c represent three different batches of salicylic acid microcapsules respectively.
The MIC values of salicylic acid and nanocapsules against 3 acne pathogens are shown in tables 3 and 4. The results show that the MICs of salicylic acid to S.aurueus, S.epidermidis and P.ace are 5, 2.5mg/g, respectively. The MICs of the nanocapsules were 2.5, 2.5mg/g for s.aureus, s.epidermidis and p.ace, respectively.
TABLE 3 MIC values of salicylic acid against 3 acne pathogens
Figure BDA0003055243160000092
Note: "-" indicates no growth of bacteria, and "+" indicates growth of bacteria.
TABLE 4 MIC values of salicylic acid grafted nanocapsules against 3 acne pathogens
Figure BDA0003055243160000093
Note: "-" indicates no growth of bacteria, and "+" indicates growth of bacteria.
Table 5 salicylic acid grafted nanocapsules solubility in water test
Figure BDA0003055243160000101
Note: "-" indicates insoluble and "+" indicates soluble.

Claims (5)

1. A preparation method of chitosan grafted salicylic acid microcapsules is characterized by comprising the following steps:
(1) putting core material salicylic acid and a compound emulsifier into a beaker, adding deionized water, and carrying out water bath reaction at 10-100 ℃ to obtain a stable negative-charged liquid drop primary emulsion polymer;
(2) preparing a chitosan solution, adding an acetic acid/sodium acetate buffer solution for dissolving, and controlling the pH value of the solution to be 3-4.5;
(3) adding the solution obtained in the step (1) into the solution obtained in the step (2), adding a noble metal catalyst, and carrying out catalytic grafting reaction in a water bath at the temperature of 10-100 ℃ to obtain a secondary emulsion of droplets with positive charges;
(4) preparing sodium alginate aqueous solution, and controlling the pH value to be 6-8;
(5) adding the secondary emulsion obtained in the step (3) into the solution obtained in the step (4), and uniformly stirring; carrying out water bath reaction at 10-100 ℃ to obtain the negative charged liquid drop tertiary emulsion.
(6) Adding the calcium chloride solution into the tertiary emulsion obtained in the step (5), and uniformly stirring; reacting in water bath at 10-100 ℃ to obtain the chitosan grafted salicylic acid microcapsule.
2. The preparation method of claim 1, wherein the mass ratio of the core material salicylic acid to the compound emulsifier in the step (1) is 1:0.1-1: 10.
3. The preparation method according to claim 1, wherein the compound emulsifier in step (1) is tween-80 and sodium lauryl amphoacetate in a weight ratio of 1:10 to 20: 1.
4. The method according to claim 1, wherein the noble metal in the step (3) is gold, palladium, molybdenum or copper.
5. A chitosan grafted salicylic acid microcapsule, characterized in that it is prepared by the method of claim 1.
CN202110498044.1A 2021-05-08 2021-05-08 Chitosan grafted salicylic acid microcapsule and preparation method thereof Pending CN113101375A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110498044.1A CN113101375A (en) 2021-05-08 2021-05-08 Chitosan grafted salicylic acid microcapsule and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110498044.1A CN113101375A (en) 2021-05-08 2021-05-08 Chitosan grafted salicylic acid microcapsule and preparation method thereof

Publications (1)

Publication Number Publication Date
CN113101375A true CN113101375A (en) 2021-07-13

Family

ID=76721335

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110498044.1A Pending CN113101375A (en) 2021-05-08 2021-05-08 Chitosan grafted salicylic acid microcapsule and preparation method thereof

Country Status (1)

Country Link
CN (1) CN113101375A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104306166A (en) * 2014-10-21 2015-01-28 中山大学惠州研究院 Salicylic acid microcapsule, preparation method and skin-protecting cream thereof
CN108541866A (en) * 2018-04-26 2018-09-18 福州大学 A kind of cinnamic acid-sodium alginate-chitosan nanoparticle and preparation method thereof
CN108743411A (en) * 2018-06-29 2018-11-06 中山大学惠州研究院 A kind of method that LBL self-assembly prepares sun-proof Nano capsule
CN111455675A (en) * 2020-04-23 2020-07-28 罗莱生活科技股份有限公司 Skin-care microcapsule and preparation method and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104306166A (en) * 2014-10-21 2015-01-28 中山大学惠州研究院 Salicylic acid microcapsule, preparation method and skin-protecting cream thereof
CN108541866A (en) * 2018-04-26 2018-09-18 福州大学 A kind of cinnamic acid-sodium alginate-chitosan nanoparticle and preparation method thereof
CN108743411A (en) * 2018-06-29 2018-11-06 中山大学惠州研究院 A kind of method that LBL self-assembly prepares sun-proof Nano capsule
CN111455675A (en) * 2020-04-23 2020-07-28 罗莱生活科技股份有限公司 Skin-care microcapsule and preparation method and application thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
刘瑞雪等主编: "《高分子材料》", 30 September 2018 *
张珊珊等: ""乳液模板-层层自组装法制备百里香精油微胶囊"", 《食品工业》 *
赵明月等: ""喷雾干燥法制备壳寡糖/水杨酸微胶囊"", 《精细化工》 *
黄 晶等: ""层层自组装法制备百里香精油微胶囊条件优化"", 《食品科学》 *

Similar Documents

Publication Publication Date Title
CN111317135A (en) Method for embedding slow-release curcumin by polyphenol-modified zein nanoparticles
CN105054070B (en) A kind of Sophora viciifolia color glycosides crude extract and its microcapsules
CN102924929B (en) Nanoparticles for encapsulating polyphenol active substances and preparation method thereof
Banerjee et al. Modified chitosan encapsulated core-shell Ag Nps for superior antimicrobial and anticancer activity
CN111956618B (en) Preparation method and application of lignin-based antitumor drug carrier
CN101724163B (en) Composite microsphere of chitosan derivative, preparing method and applications thereof
CN110384684B (en) Monocarboxyl chitosan/alkannin composite nano-particles and preparation method thereof
CN114009444B (en) Preparation and application of multifunctional Janus mesoporous silica nano-drug fertilizer
Mandava Biological and non-biological synthesis of metallic nanoparticles: Scope for current pharmaceutical research
CN113577376A (en) Double-heavy-load drug polysaccharide-based self-healing hydrogel and preparation method thereof
Stoica et al. Evaluation of natural polyphenols entrapped in calcium alginate beads prepared by the ionotropic gelation method
Chatterjee et al. Chitosan: source, chemistry, and properties
CN101519475B (en) Method for preparing rotenone/carboxymethyl chitosan grafting ricinoleic acid nanometer grain water dispersing agent
CN108541866A (en) A kind of cinnamic acid-sodium alginate-chitosan nanoparticle and preparation method thereof
Manne et al. Pterocarpus marsupium Roxb. heartwood extract synthesized chitosan nanoparticles and its biomedical applications
CN111514097B (en) Preparation method of pH-responsive nano hydrogel of walnut shell polyphenol
CN108096214B (en) Magnetotactic bacteria quantum dot microcapsule and preparation method thereof
Falsafi et al. Metal nanoparticles and carbohydrate polymers team up to improve biomedical outcomes
Yang et al. Controlled chitosan molecular weight reduction by mechanochemical and aging-based phosphoric acid hydrolysis
CN113615706A (en) Water-soluble composite sustained-release agent and preparation method thereof
CN113455504B (en) Chitosan-loaded caffeic acid ester nano-medicament and preparation method and application thereof
CN107737043B (en) Hyaluronic acid-based tea polyphenol-loaded self-assembled nano-composite, and preparation method and application thereof
CN113101375A (en) Chitosan grafted salicylic acid microcapsule and preparation method thereof
Lin et al. Effect of Acid Type, Acetic Acid and Sodium Carboxymethyl Cellulose Consentrations on the Formation, Micromeritic, Dissolution and Floating Properties of Theophylline Chitosan Microcapsules
CN104127386A (en) Rubimaillin/chitosan nanoparticle, and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210713

WD01 Invention patent application deemed withdrawn after publication